DUBLIN--(BUSINESS WIRE)-- Elan Corporation, plc (ELN) announces that the information statement in respect of Prothena Corporation plc, which is being provided to holders of record of Elan ordinary shares and ADSs as of December 14, 2012 and which describes the separation and distribution of the Prothena Business in detail and contains important business and financial information about Prothena, has been published. The information statement is now available on Elans website at www.elan.com.

About Elan

Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the Company, please visit www.elan.com.

Elan Corporation, plc
Investor Relations:
Chris Burns, 800-252-3526
David Marshall, 353-1-709-4444
Media Relations:
Emer Reynolds, + 353-1-709-4022
Jonathan Birt, +44-751-559-7858

Source: Elan Corporation, plc